Nifty
Sensex
:
:
11987.65
40639.29
-11.45 (-0.10%)
-12.35 (-0.03%)

Pharmaceuticals & Drugs

Rating :
59/99  (View)

BSE: 500124 | NSE: DRREDDY

2871.35
32.70 (1.15%)
21-Nov-2019 | 12:04PM
  • Day's Open
  • Day's High
  • Day's Low
  • Previous Close
  •  2828.00
  •  2876.55
  •  2810.20
  •  2838.65
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  541160
  •  15538.60
  •  2964.00
  •  1872.95

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 47,146.35
  • 17.21
  • 5
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 50,761.65
  • 0.70%
  • 3.06

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 26.76%
  • 3.86%
  • 7.59%
  • FII
  • DII
  • Others
  • 0.21%
  • 14.69%
  • 46.89%

Chart

Price | P:E | P:BV | EV:EBITDA

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.26
  • 0.56
  • 2.86

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 8.35
  • -1.87
  • 5.15

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 18.42
  • -3.99
  • 14.88

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • 24.06
  • 28.45
  • 31.83

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 4.57
  • 4.06
  • 3.26

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • 16.62
  • 17.19
  • 16.14

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Sep 19
Sep 18
Var%
Jun 19
Jun 18
Var%
Mar 19
Mar 18
Var%
Dec 18
Dec 17
Var%
Net Sales
4,812.80
3,817.50
26.07%
3,858.20
3,736.50
3.26%
4,029.60
3,553.90
13.39%
3,864.60
3,834.10
0.80%
Expenses
3,749.00
3,058.20
22.59%
3,116.50
2,967.70
5.01%
3,210.70
2,990.30
7.37%
3,060.00
3,041.40
0.61%
EBITDA
1,063.80
759.30
40.10%
741.70
768.80
-3.52%
818.90
563.60
45.30%
804.60
792.70
1.50%
EBIDTM
22.10%
19.89%
19.22%
20.58%
20.32%
15.86%
20.82%
20.68%
Other Income
54.00
128.20
-57.88%
430.10
50.40
753.37%
83.30
44.90
85.52%
102.30
43.00
137.91%
Interest
30.30
20.80
45.67%
29.80
19.50
52.82%
24.50
17.80
37.64%
24.10
17.20
40.12%
Depreciation
313.10
278.60
12.38%
289.00
278.70
3.70%
287.20
276.30
3.94%
290.30
271.50
6.92%
PBT
774.40
588.10
31.68%
853.00
521.00
63.72%
590.50
314.40
87.82%
592.50
547.00
8.32%
Tax
-320.70
80.70
-
192.80
53.20
262.41%
150.80
49.20
206.50%
101.10
252.80
-60.01%
PAT
1,095.10
507.40
115.83%
660.20
467.80
41.13%
439.70
265.20
65.80%
491.40
294.20
67.03%
PATM
22.75%
13.29%
17.11%
12.52%
10.91%
7.46%
12.72%
7.67%
EPS
66.59
31.22
113.29%
40.70
28.68
41.91%
27.43
16.39
67.36%
30.14
18.26
65.06%

Annual Results

Consolidated Figures in Rs. Crores /

Standalone
Description
TTM
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Net Sales
16,565.20
15,448.20
14,281.00
14,196.10
15,568.30
15,023.30
13,415.30
11,895.60
9,814.50
7,496.90
6,988.60
Net Sales Growth
10.86%
8.17%
0.60%
-8.81%
3.63%
11.99%
12.78%
21.20%
30.91%
7.27%
 
Cost Of Goods Sold
5,046.20
4,494.80
4,039.50
3,696.50
3,758.50
3,786.40
3,317.10
3,516.80
2,568.30
2,091.10
2,061.70
Gross Profit
11,519.00
10,953.40
10,241.50
10,499.60
11,809.80
11,236.90
10,098.20
8,378.80
7,246.20
5,405.80
4,926.90
GP Margin
69.54%
70.90%
71.71%
73.96%
75.86%
74.80%
75.27%
70.44%
73.83%
72.11%
70.50%
Total Expenditure
13,136.20
12,270.00
11,929.80
11,723.90
11,983.00
11,529.70
10,164.70
9,176.10
7,374.90
5,936.00
5,563.50
Power & Fuel Cost
-
329.10
329.30
330.10
315.20
339.10
319.90
335.40
225.90
183.30
141.50
% Of Sales
-
2.13%
2.31%
2.33%
2.02%
2.26%
2.38%
2.82%
2.30%
2.45%
2.02%
Employee Cost
-
3,356.20
3,214.90
3,106.80
3,117.40
2,944.60
2,475.40
1,928.70
1,591.20
1,304.80
1,183.20
% Of Sales
-
21.73%
22.51%
21.88%
20.02%
19.60%
18.45%
16.21%
16.21%
17.40%
16.93%
Manufacturing Exp.
-
1,434.80
1,746.50
1,886.60
1,856.40
1,999.10
1,747.60
1,441.30
1,237.00
985.90
921.80
% Of Sales
-
9.29%
12.23%
13.29%
11.92%
13.31%
13.03%
12.12%
12.60%
13.15%
13.19%
General & Admin Exp.
-
1,143.70
1,193.40
1,339.90
1,271.40
1,037.30
1,004.30
796.30
682.90
479.00
413.50
% Of Sales
-
7.40%
8.36%
9.44%
8.17%
6.90%
7.49%
6.69%
6.96%
6.39%
5.92%
Selling & Distn. Exp.
-
1,423.50
1,330.20
1,293.40
1,181.10
1,357.50
1,264.80
1,119.10
984.40
744.90
691.00
% Of Sales
-
9.21%
9.31%
9.11%
7.59%
9.04%
9.43%
9.41%
10.03%
9.94%
9.89%
Miscellaneous Exp.
-
87.90
76.00
70.60
483.00
65.70
35.60
38.50
85.20
147.00
691.00
% Of Sales
-
0.57%
0.53%
0.50%
3.10%
0.44%
0.27%
0.32%
0.87%
1.96%
2.16%
EBITDA
3,429.00
3,178.20
2,351.20
2,472.20
3,585.30
3,493.60
3,250.60
2,719.50
2,439.60
1,560.90
1,425.10
EBITDA Margin
20.70%
20.57%
16.46%
17.41%
23.03%
23.25%
24.23%
22.86%
24.86%
20.82%
20.39%
Other Income
669.70
337.50
155.20
171.50
295.00
274.10
169.90
149.90
132.30
52.30
103.10
Interest
108.70
88.90
78.80
63.40
82.60
108.20
126.70
100.30
114.10
32.30
38.50
Depreciation
1,179.60
1,134.80
1,077.20
1,026.60
938.90
759.90
647.50
550.20
518.10
398.10
413.10
PBT
2,810.40
2,292.00
1,350.40
1,553.70
2,858.80
2,899.60
2,646.30
2,218.90
1,939.70
1,182.80
1,076.60
Tax
124.00
385.80
438.00
296.50
751.10
563.20
683.10
637.90
503.50
183.90
266.80
Tax Rate
4.41%
16.83%
32.43%
19.08%
26.27%
19.42%
25.81%
29.47%
27.90%
15.55%
43.15%
PAT
2,686.40
1,906.20
912.40
1,257.20
2,107.70
2,336.40
1,963.20
1,526.80
1,300.90
998.90
351.50
PAT before Minority Interest
2,686.40
1,906.20
912.40
1,257.20
2,107.70
2,336.40
1,963.20
1,526.80
1,300.90
998.90
351.50
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
16.22%
12.34%
6.39%
8.86%
13.54%
15.55%
14.63%
12.83%
13.25%
13.32%
5.03%
PAT Growth
75.06%
108.92%
-27.43%
-40.35%
-9.79%
19.01%
28.58%
17.36%
30.23%
184.18%
 
Unadjusted EPS
164.86
117.53
57.08
77.53
124.93
137.18
115.45
89.93
76.76
59.06
20.83

Results Balance Sheet

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Shareholder's Funds
14,023.60
12,571.60
12,262.10
12,569.80
9,853.10
7,865.20
6,369.10
4,989.00
4,031.90
3,776.80
Share Capital
83.00
83.00
82.90
85.30
85.20
85.10
84.90
84.80
84.60
84.40
Total Reserves
13,861.10
12,406.00
12,098.80
12,393.90
9,677.40
7,698.60
6,215.30
4,849.10
3,906.80
3,657.40
Non-Current Liabilities
2,113.00
2,538.40
456.10
876.70
1,678.40
2,182.30
1,285.10
1,609.80
600.30
1,491.00
Secured Loans
55.20
63.00
59.70
74.70
77.50
94.70
80.20
26.10
24.40
26.90
Unsecured Loans
2,144.80
2,445.90
485.20
993.80
1,354.00
1,980.80
1,185.70
1,615.80
512.80
1,457.10
Long Term Provisions
79.30
81.70
84.20
95.20
77.90
56.30
51.40
33.30
28.80
0.00
Current Liabilities
5,897.30
6,893.80
8,419.90
6,347.10
6,821.30
5,790.40
5,658.80
4,591.40
4,208.50
2,024.80
Trade Payables
1,367.10
1,334.50
1,056.90
906.80
867.30
893.20
965.70
756.60
634.50
1,667.90
Other Current Liabilities
2,820.70
2,411.40
2,339.70
2,409.10
2,624.40
2,020.80
2,120.40
1,749.20
1,328.90
6.70
Short Term Borrowings
1,212.50
2,556.20
4,362.60
2,271.80
2,185.70
2,060.70
1,898.60
1,588.80
1,831.90
0.00
Short Term Provisions
497.00
591.70
660.70
759.40
1,143.90
815.70
674.10
496.80
413.20
350.20
Total Liabilities
22,033.90
22,003.80
21,138.10
19,793.60
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70
7,292.60
Net Block
7,191.00
6,968.00
6,930.70
6,563.00
5,377.00
4,640.80
4,050.60
3,411.70
3,385.50
2,352.20
Gross Block
18,048.40
17,436.30
15,932.40
15,019.70
12,573.60
11,917.60
10,089.40
8,842.30
7,975.10
6,446.80
Accumulated Depreciation
10,845.80
10,468.30
9,001.70
8,456.70
7,169.90
7,276.80
5,984.60
5,295.30
4,589.60
4,094.60
Non Current Assets
10,923.80
11,505.40
11,454.40
7,999.60
6,476.10
5,512.20
4,786.30
4,191.20
4,025.70
3,115.00
Capital Work in Progress
2,933.50
3,470.50
3,324.50
772.20
529.00
638.80
565.30
708.50
575.20
762.20
Non Current Investment
334.20
465.30
682.60
329.70
145.60
0.40
0.40
0.90
0.90
0.60
Long Term Loans & Adv.
426.70
564.80
482.10
290.40
418.10
232.20
149.10
70.10
64.10
0.00
Other Non Current Assets
38.40
36.80
34.50
44.30
6.40
0.00
20.90
0.00
0.00
0.00
Current Assets
11,110.10
10,498.40
9,683.70
11,794.00
11,876.70
10,325.70
8,526.70
6,999.00
4,815.00
4,177.60
Current Investments
2,252.90
1,833.00
1,427.10
3,503.40
2,102.20
1,066.40
196.60
207.00
0.00
357.40
Inventories
3,357.90
2,908.90
2,852.80
2,557.90
2,569.90
2,418.80
2,170.70
1,943.30
1,599.20
1,339.40
Sundry Debtors
3,986.90
4,052.70
3,798.60
4,125.00
4,101.20
3,325.30
3,180.40
2,536.80
1,761.10
1,159.90
Cash & Bank
222.80
263.80
386.50
492.10
1,872.40
2,300.60
2,017.10
1,606.10
575.10
660.00
Other Current Assets
1,289.60
765.90
451.50
393.10
1,231.00
1,214.60
961.90
705.80
879.60
660.90
Short Term Loans & Adv.
439.80
674.10
767.20
722.50
1,004.80
1,044.20
796.90
611.60
763.20
658.70
Net Current Assets
5,212.80
3,604.60
1,263.80
5,446.90
5,055.40
4,535.30
2,867.90
2,407.60
606.50
2,152.80
Total Assets
22,033.90
22,003.80
21,138.10
19,793.60
18,352.80
15,837.90
13,313.00
11,190.20
8,840.70
7,292.60

Cash Flow

Consolidated Figures in Rs. Crores /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Cash From Operating Activity
2,870.40
1,803.00
2,144.40
3,262.60
2,523.50
1,969.70
1,377.90
1,612.60
755.40
1,315.00
PBT
2,292.00
1,350.40
1,553.70
2,858.80
2,899.60
2,646.30
2,164.70
1,804.40
1,182.80
618.30
Adjustment
1,639.60
1,625.30
1,687.30
1,107.70
1,654.00
1,042.70
1,062.80
1,157.40
530.10
1,117.30
Changes in Working Capital
-577.10
-896.60
-519.60
-2.50
-1,483.70
-1,005.00
-1,294.40
-893.80
-658.70
-137.50
Cash after chg. in Working capital
3,354.50
2,079.10
2,721.40
3,964.00
3,069.90
2,684.00
1,933.10
2,068.00
1,054.20
1,598.10
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-484.10
-276.10
-577.00
-701.40
-546.40
-714.30
-555.20
-455.40
-298.80
-283.10
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
-772.70
-1,488.30
-1,840.40
-2,039.40
-2,264.70
-1,694.10
-1,446.30
-1,888.40
-898.80
-710.20
Net Fixed Assets
-275.60
-683.20
-1,019.30
-1,892.20
-828.10
-819.60
-530.80
-554.40
-399.90
-602.60
Net Investments
-297.00
-534.60
1,974.20
-1,213.80
-1,055.80
-427.30
98.50
-15.70
93.10
-851.30
Others
-200.10
-270.50
-2,795.30
1,066.60
-380.80
-447.20
-1,014.00
-1,318.30
-592.00
743.70
Cash from Financing Activity
-2,132.60
-444.00
-369.20
-1,700.10
-433.20
-24.20
-156.80
389.10
44.50
-531.70
Net Cash Inflow / Outflow
-34.90
-129.30
-65.20
-476.90
-174.40
251.40
-225.20
113.30
-98.90
73.10
Opening Cash & Equivalents
254.20
377.80
492.10
539.50
862.40
520.40
736.20
573.00
660.00
562.30
Closing Cash & Equivalent
222.80
254.20
377.80
492.10
582.90
862.40
520.40
736.20
575.10
660.00

Financial Ratios

Consolidated /

Standalone
Description
Mar 19
Mar 18
Mar 17
Mar 16
Mar 15
Mar 14
Mar 13
Mar 12
Mar 11
Mar 10
Book Value (Rs.)
840.01
752.35
734.72
731.49
572.92
457.33
371.04
290.91
235.90
221.67
ROA
8.66%
4.23%
6.14%
11.05%
13.67%
13.47%
12.46%
12.99%
12.38%
4.82%
ROE
14.42%
7.40%
10.20%
18.95%
26.63%
27.88%
27.18%
29.15%
25.83%
9.72%
ROCE
13.41%
8.21%
9.77%
19.55%
22.69%
24.77%
24.79%
26.24%
20.84%
12.18%
Fixed Asset Turnover
0.87
0.86
0.92
1.13
1.23
1.23
1.26
1.17
1.04
1.09
Receivable days
94.98
100.33
101.86
96.43
89.72
87.97
87.19
79.59
70.77
67.20
Inventory Days
74.03
73.63
69.56
60.11
60.27
62.06
62.74
65.60
71.20
68.85
Payable days
39.46
37.10
31.00
28.67
28.48
33.96
34.99
35.37
72.19
108.29
Cash Conversion Cycle
129.55
136.86
140.42
127.87
121.51
116.06
114.93
109.82
69.78
27.76
Total Debt/Equity
0.28
0.41
0.40
0.27
0.44
0.58
0.58
0.66
0.59
0.40
Interest Cover
26.78
18.14
25.51
35.61
27.80
21.89
22.58
16.81
37.62
17.06

News Update


  • Dr. Reddy’s Laboratories launches diabetes nutrition drink ‘Celevida’ in India
    14th Nov 2019, 15:51 PM

    It’s a first-of-its-kind under company's nutrition portfolio and clinically proven to help manage blood glucose levels among Indian patients

    Read More
  • Dr Reddy’s Laboratories wins ‘API Supplier of the Year’ award
    13th Nov 2019, 11:49 AM

    The award acknowledges the company’s proactive and methodical approach in addressing the global Sartan APIs concern

    Read More
  • Dr. Reddy's Laboratories reports over 2-fold jump in Q2 consolidated net profit
    1st Nov 2019, 11:46 AM

    Total consolidated income of the company increased by 23.34% at Rs 4,866.80 crore for Q2FY20

    Read More
  • Dr. Reddys Lab - Quarterly Results
    1st Nov 2019, 11:25 AM

    Read More
  • USFDA completes inspection at Dr. Reddy's Lab’s API Srikakulam plant
    29th Oct 2019, 09:19 AM

    The company has been issued a Form 483 with 4 observations

    Read More
  • Dr. Reddy's Lab gets EIR for Formulations Manufacturing facility at USA
    23rd Oct 2019, 15:27 PM

    The inspection classification of this facility is determined as No Action Indicated

    Read More
  • Dr. Reddy's Lab confirms its voluntary nationwide recall of all Ranitidine products in US
    23rd Oct 2019, 14:07 PM

    This recall follows the USFDA's caution note alerting patients and health care professionals that NDMA was found in certain samples of ranitidine

    Read More
  • Dr. Reddy's Lab gets EIR for API manufacturing at Hyderabad
    7th Oct 2019, 10:27 AM

    The company has received EIR from US Food and Drug Administration

    Read More
  • Dr. Reddy's Lab suspends worldwide supply of Ranitidine
    23rd Sep 2019, 10:01 AM

    Ranitidine is an OTC and prescription drug which decreases the amount of acid created by the stomach

    Read More
  • Dr. Reddy's Lab launches Lansoprazole Delayed-Release Capsules in US market
    16th Sep 2019, 11:52 AM

    Dr. Reddy's OTC Lansoprazole Delayed-Release Capsules USP, 15 mg, is an over-the-counter, PPI used to treat frequent heartburn occurring two or more days a week

    Read More
  • Dr. Reddy's Lab gets EIR from USFDA for manufacturing plants at Visakhapatnam
    13th Sep 2019, 09:49 AM

    The agency had conducted an audit of the company’s formulations manufacturing plants at Duvvada

    Read More
  • Dr. Reddy's Lab launches Bupropion Hydrochloride Extended-Release Tablets
    5th Sep 2019, 12:47 PM

    The Zyban brand and generic had US sales of approximately $5.4 million

    Read More
  • Dr Reddy's gets 8 observations from USFDA for its Duvvada facility
    21st Aug 2019, 09:56 AM

    The company has been issued Form 483 with 8 observations

    Read More
  • Dr. Reddy’s Lab launches Vigabatrin Powder for Oral Solution
    20th Aug 2019, 11:08 AM

    Vigabatrin Powder for Oral Solution, USP is available in 500 mg per packet in count size of 50 per carton

    Read More
  • Dr. Reddy’s Lab launches Versavo in India
    19th Aug 2019, 12:51 PM

    The company now has six biosimilar products commercialized in India

    Read More
  • Dr. Reddy’s Lab get CRL from USFDA for NuvaRing, Copaxone
    16th Aug 2019, 11:36 AM

    Copaxone is a multi-billion dollar drug and a prescription medicine used for the treatment of people with relapsing forms of multiple sclerosis

    Read More

Source: www.accordfintech.com. Price feed provided by www.nseindia.com and www.bseindia.com value addition by www.accordfintech.com. Intraday data delayed 15 minutes.

DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.